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ABSTRACT 
Objective: Tuberculosis is an airborne infection caused by Mycobacterium tuberculosis. Timely diagnosis and treatment are important to prevent 
the spread of infection. Cartridge-based nucleic acid amplification test (CBNAAT) provides a valuable tool in the early detection of TB. This study is 
undertaken to evaluate the utility of CBNAAT for the detection of MTB. Comparison of cartridge-based nucleic acid amplification testing with ZN 
staining. 
Methods: This prospective observational study was carried out in the Department of Microbiology, BLDEDU’s Shri B. M. Patil Medical College, 
Hospital and RC and Dr. Karigoudar Diagnostic Laboratory, Vijayapur. A total of 129 samples from patients with the presumptive diagnosis of TB 
based on history, clinical presentation, and radiological findings were included in the study. All samples were subjected to ZN staining, and 
Cartridge-based nucleic acid amplification test and data were analyzed. 
Results: The present study showed ZN smear positivity of 7.75% and CBNAAT positivity of 19.38%. CBNAAT sensitivity and specificity were 90% 
and 86.55, respectively, compared with ZN staining with a significant P value of <0.001.  
Conclusion: CBNAAT helps diagnose TB and detect rifampicin resistance within 2-3 h with high sensitivity and specificity. Rifampicin resistance 
detection is of great concern, which otherwise leads to treatment failure and on time spread of multidrug resistance TB, leading to increased 
morbidity and mortality.  
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INTRODUCTION 
Tuberculosis (TB) is a communicable disease caused by the bacillus 
Mycobacterium tuberculosis (MTB), an airborne infection. It causes 
pulmonary TB (PTB) involving lungs in about 85-90% of cases and 
extrapulmonary TB (EPTB) involving pleura, the lymphatic 
system, the central nervous system, the bones and joints, and 
the genitourinary system accounting for about 15-20% of TB cases. 
TB is a major global health problem in developing countries. Globally 
around 10 million people suffer from TB infection every year, 
accounting for one-third of the world's population. The increased 
occurrence of TB in underdeveloped countries is due to poor 
hygienic conditions, overcrowding, and the increased occurrence of 
HIV infection. India contributes to one-fourth of the world’s TB 
burden. According to WHO 2018 report, India was having the 
world's largest number of TB patients. As of 2019, India reported the 
largest number of individuals suffering from drug-resistant TB. As of 
2019 report, 21.5 lakh cases were notified as TB compared to 18.3 
lakh cases of TB in 2018. This is mainly due to the rapid cartridge-
based nucleic acid amplification test (CBNAAT) method for the early 
TB diagnosis. With timely detection and treatment, most TB cases 
can be cured, and the forward spread of infection can be reduced [1]. 
Prompt and accurate detection of TB is needed for early and 
effective treatment, thereby reducing the burden of TB [2]. The 
overall priority for TB care and control is to improve early case-
detection. Hidden undiagnosed cases of TB are of major global 
concern. The innovation of CBNAAT is an important tool to fight 
against TB. CBNAAT provides a valuable tool in the early detection of 
smear-negative PTB, EPTB, TB-HIV, and Multidrug-resistant 
tuberculosis (MDR-TB). Its high sensitivity, specificity, and less 
turnaround time for timely diagnosis of pulmonary and 
extrapulmonary cases and detection of resistance towards 
rifampicin provide a potential role for controlling TB infection [3]. 
The CBNAAT has advantages over conventional methods for 
diagnosing tuberculosis (TB) and detecting rifampicin-resistance. It 
is very costly. So in a low-resource hospital setup, CBNAAT must be 
used in a manner that will have the peak impact on patient care. In 
this context, the present study was undertaken to evaluate the utility 
of CBNAAT for the detection of MTB and to compare CBNAAT with 
ZN staining. 
MATERIALS AND METHODS 
This Prospective observational study was carried out in the 
Department of Microbiology, BLDEDU’s Shri B. M. Patil Medical 
College, Vijayapur and Dr. Karigoudar Diagnostic Laboratory, 
Vijayapur. The study duration was from March 2018 to August 2019. 
Patients with the presumptive diagnosis of TB based on history, 
clinical presentation, and radiological findings were included in the 
study. A total of 129 samples collected from suspected patients were 
included in the present study. The patients on treatment with TB 
drugs in the last 2 mo were excluded from this study. From each 
patient, either a minimum of 5.0  ml of sputum sample or 2 ml of fluid 
(CSF, pus, ascitic fluid, and pericardial fluid) and aspirate from 
lymph nodes were collected according to standard protocol. All 
samples were subjected to Ziehl–Neelsen staining and CBNAAT, and 
data were analyzed. 
CBNAAT is a polymerase chain reaction (PCR) based method for the 
detection of TB and resistance to Rifampicin. CBNAAT device is a 
disposable, single-use, self-enclosed cartridge with automated 
sample processing, amplification, and detection facility. The sample 
reagent will be added to the sample in a 2:1 ratio to liquefy and 
inactivate the bacteria in the sample, 2 ml sampled into the 
cartridge, and loaded into the assay procedure device. All further 
steps are automated. The test results are categorized into the 
following result patterns: No-MTB detected; MTB detected-
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Rifampicin resistance detected; MTB detected no rifampicin 
resistance detected; MTB detected rifampicin resistance 
indeterminate, and an invalid result [3]. 
Statistical analysis 
Statistical analyses were performed using SPSS version 20.0 
software for MS-Windows. P-value was calculated using the Chi-
Square test (P-value of <0.05 = significant). 
RESULTS 
A total of 129 samples collected from the patients suspected of 
tuberculosis based on clinical and radiological findings were 
analyzed. The most common age group suspected of TB was from 
21-40 y (41.08%), followed by 41-60 y (24.03%). The mean age of 
the subject was found to be 33.55±19. In that, 59.56 (43.41%) were 
males, and 73 (56.59%) were females with a ratio of 1:1.3 (M: F). 
Samples included lymph node aspirate 42 (32.56%), sputum 25 
(19.38%), CSF 17 (13.18%), endometrial tissue10 (7.75%), synovial 
fluid 3 (2.33%) and others like Urine, Stool, Peritoneal fluid 32 
(24.81%) among 129 samples. All these 129 samples were subjected 
to Ziehl Neelsen staining and CBNAAT. Out of these 129 samples 
subjected to Ziehl Neelsen staining, 10 (7.75%) samples were 
smear-positive, and 119 (92.25%) were smear-negative for acid-fast 
bacilli. All these samples were also tested by CBNAAT, which showed 
25 (19.38%) MTB positive, and 104 (80.62%) MTB negative. The 
CBNAAT detected MTB in 09 out of 10 ZN smear-positive and 15 out 
of 115 ZN smear-negative cases. The present study showed ZN 
smear positivity (7.75%) and CBNAAT positivity (19.38%) with 
CBNAAT sensitivity and specificity of 90% and 86.55% when 
compared with ZN staining with a significant P value of <0.0001. 
CBNAAT showed 100% sensitivity and 100% specificity when 
compared to ZN staining for pulmonary samples. In the same way, 
when the CBNAAT results are compared with ZN staining for extra 
pulmonary samples, CBNAAT showed 87.5% sensitivity and 81.18% 
specificity. Out of 25 positives for MTB by CBNAAT, MTB was 
detected in 15 cases. Among the 15 cases, females (08) and males 
(07) were 21-40 y old. In the age group 41-60 y, MTB was detected 
in 5 cases, male (04) and female (01). In the age group <20 y, 4 cases 
showed MTB positive results, and all were females. In >60 y, 1 MTB 
was detected in male patient. Overall, MTB was detected in high 
number among males (21.43%) than females (17.81%) by CBNAAT. 
Age, sex, and sample-wise distribution of MTB detection by assay 
have been shown in fig. 1 and 2. Out of 25 detected for MTB by 
CBNAAT, 10 were tested for rifampicin resistance; in that 10, 2 
(20%) were rifampicin resistance, and the remaining 08 (80%) were 




Fig. 1: Age and sex-wise detection of MTB by CBNAAT 
 
 
Fig. 2: Sample wise detection of MTB by CBNAAT 
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Fig. 3: Rifampicin resistance testing by CBNAAT 
 
Table 1: Comparison of CBNAAT with ZN stain (pulmonary and extrapulmonary samples) 
Test ZN stain 
CBNAAT Positive Negative Total % 
Positive 9 16 25 19.38 
Negative 01 103 104 80.62 
Total 10 119 129 100 
% 7.75 92.25 100  
χ2
  
= 29876, P<0.0001, Sensitivity = 90%, Specificity = 86.55%, Positive predictive value =36%, Negative predictive value =99.04% 
Table 2: Comparison of CBNAAT with ZN stain (Pulmonary Sample) 
Test ZN stain 
CBNAAT Positive Negative Total % 
Positive 2 0 2 6 
Negative 0 34 34 94 
Total 2 34 36 100 
% 6% 94% 100  
χ2
 
= 19.434, P<0.0001, Sensitivity = 100%, Specificity = 100%, Positive predictive value =100%, Negative predictive value =100% 
Table 3: Comparison with CBNAAT ZN stain (Extra Pulmonary Sample) 
Test ZN stain 
CBNAAT Positive Negative Total % 
Positive 7 16 23 25 
Negative 1 69 70 75 
Total 8 85 93 100 
% 9% 91% 100  
χ2
 
= 15.02, P = 0.0001, Sensitivity = 87.5%, Specificity = 81.18%, Positive predictive value =30.43%, Negative predictive value =98.57% 
DISCUSSION 
India has more than a million cases each year that are not notified 
and remain undiagnosed [4]. According to the World Health 
Organization, in 2019, India continued at the top list, with 
tuberculosis (TB) having the majority number of MDR-TB cases. 
Early and effective treatment depends on the timely diagnosis of TB. 
The overall main concern for TB care and control is to improve early 
case-detection, mainly in ZN smear-negative PTB and EPTB. EPTB 
diagnosis is considered a major concern because clinical samples 
obtained from inaccessible sites may have a low bacillary load, thus 
decreasing diagnostic test's sensitivity. As a result, an enormous 
number of undiagnosed cases of TB will be missed out, leading to a 
serious global health issue [5]. 
TB affects all ages. In India, the infection rate is 20% at the age of 
15–24 y age and 2% in 0–14 y of age group. In a developed country, 
the disease is more common in the older age group and more 
prevalent in males than females [6]. The present study analyzed 129 
samples obtained from patients suspected of TB based on clinical 
and radiological findings. The most common age group suspected of 
TB was from 21-40 y (41.08%), followed by 41-60 y (24.03%). The 
mean age of the subjects was found to be 33.55±19.59. Males were 
56 (43.41%), and females were 73 (56.59%) with a 1: 1.3 (M: F) 
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ratio. In another study, 194 (48.1%) were females, and 209 (51.9%) 
were males with M: F ratio of 1: 1.08. The mean age of the subjects 
found to be 35.3±15.9. Most subjects (40.9%) were in 21-35 y of age 
[7]. In another study, the mean age of the subjects was 33±17.13 y 
[8]. These findings were in concordance with our findings of the 
present study.  
The highest number of samples were from Lymph node aspirate 42 
(32.56%), sputum 25 (19.38%), followed by CSF 17 (13.18%), 
endometrial tissue 10 (7.75%), synovial fluid 3 (2.33%), and others 
like urine, stool, peritoneal fluid 32 (24.81%). In contrast to our 
study, the other study included 387 (96.0%) sputum and 7 (1.7%) 
bronchial wash, extrapulmonary samples 9 (2.3%) [6]. Most of the 
clinicians focus on ZN smears positive patients who are highly 
infectious. Patients with ZN smear-negative are also accountable for 
about 17% of transmission of TB infection, which could not be 
ignored and has a high impact on public health [9]. 
The present study showed ZN smear positivity (7.75%) and CBNAAT 
positivity (19.38%) with CBNAAT sensitivity and specificity of 90% 
and 86.55% when compared with ZN staining with a significant P 
value of <0.0001. In a study conducted at Mayo Hospital Lahore, 
CBNAAT reported 90.1% and 98.3% of sensitivity and specificity for 
MTB detection compared to ZN smear, 77.7% and 91.4% sensitivity 
specificity, respectively. Among 130 ZN smear-negative cases, 52 
(40.0%) were MTB positive by CBNAAT. Of the 13 ZN smear-
positive, CBNAAT detected MTB in 9 (69.2%) while 4 (30.8%) were 
of non-tubercle mycobacteria based on Para-nitro-benzoic acid test. 
Delay in the diagnosis of ZN Smear negative TB possesses difficulties 
in the treatment aspect. In such cases, early diagnosis and timely 
treatment are most important. If we go for the culture, it takes 
around 6-8 w for MTB detection. Newer diagnostic technique such 
as CBNAAT helps in increased TB detection rate rapidly. We can 
treat the patient at the earliest and can prevent the patient from 
becoming infectious for others [7]. A recently published study by 
Buchelli Rmirez HL et al. showed lower ZN smear positivity of 53% 
and higher MTB positivity of 82% by CBNAAT [10]. In the present 
study, the CBNAAT showed 100% sensitivity and 100% specificity 
for pulmonary samples than ZN staining. In the same way, when 
CBNAAT results are compared with ZN staining for extrapulmonary 
samples, CBNAAT showed 87.5% sensitivity and 81.18% specificity. 
This may be because of low bacillary load in extrapulmonary 
samples, with smear-negative and CBNAAT positive results. Based 
on the above facts, the CBNAAT assay forms an important diagnostic 
tool for diagnosing extrapulmonary tuberculosis for early treatment 
and preventing disease spread. 
Bajrami et al. reported 24.1% MTB positive by culture, while 29.3% 
MTB positive by CBNAAT. Compared with culture, the CBNAAT 
assay achieved 82.3% sensitivity and specificity [11]. In the present 
study, CBNAAT detected MTB with 87.5% sensitivity and 81.18% 
specificity among extrapulmonary samples compared with ZN 
staining. In our study, one sample was not detected for 
mycobacterium tuberculosis by CBNAAT but was positive by ZN 
staining. This may be due to non-mycobacterium tuberculosis found 
to ZN staining positive and CBNAAT result negative. The present 
study showed that ZN staining and CBNAAT for MTB detection 
improve the case detection rate. In a study conducted at Hyderabad, 
CBNAAT for pulmonary samples showed the sensitivity and 
specificity of 79.2% and 89.5%, respectively, and for 
extrapulmonary samples, the sensitivity and specificity of 85.7% and 
93.5%, respectively. The above study suggested that CBNAAT has 
higher sensitivity for detecting pulmonary and extrapulmonary 
tuberculosis cases [12]. 
Panayotis et al. observed CBNAAT sensitivity of 90.6% and specificity 
of 94.3% among the 80 pulmonary samples [13]. Similarly, in another 
study, the sensitivity of CBNAAT was 79% among all pulmonary 
samples. The CBNAAT showed a higher sensitivity for lymph node 
aspiration (94.74%) than ZN smear positivity (73.68%). Similarly, the 
present study also showed a higher sensitivity for lymph node aspirate 
(96.43%) by CBNAAT than ZN staining. Clearly, it indicates CBNAAT 
would increase the early detection of lymph node tuberculosis 
compared to and in addition to the ZN staining on FNAC aspirate 
material [14]. Steingart et al., as part of a WHO, developed updated 
guidelines and observed higher sensitivity and specificity in TB 
suspected patients, with or without HIV co-infection on the utility of 
the CBNAAT method [15]. A study from South Africa also certified that 
ZN stained microscopy of sputum smears combined with detection of 
MTB by CBNAAT is the most cost-effective strategy for diagnosis of ZN 
smear-negative TB [16]. 
Studies done from various places of different countries by the 
CBNAAT method were showed variations in their sensitivity and 
specificity. These variations in sensitivity and specificity by CBNAAT 
assay can be explained by differences in their inclusion and 
exclusion criteria. Detection of MTB by conventional methods has 
lower sensitivity and time consuming [13]. Molecular methods like 
the CBNAAT technique have transformed TB detection with rapid 
diagnosis, high sensitivity, and specificity. 
The emergence of MDR-TB and extensively drug-resistant tuberculosis 
(XDR-TB) makes the treatment and control of tuberculosis difficult. 
Rapid detection of drug-resistant strains is important for the 
successful treatment of drug-resistant tuberculosis [17]. CBNAAT 
allows early and rapid detection of rifampicin resistance, facilitating 
early drug resistance detection [15]. The specificity of CBNAAT in 
detecting rifampicin resistance was very high (98%) [18]. In our 
present study, out of 25 detected for MTB by CBNAAT, 15 were not 
tested due to low bacillary load, 10 were tested for Rifampicin 
resistance; of these 10, 2 (20%) were rifampicin resistance, and the 
remaining 8 (80%) were sensitive to rifampicin. In a study where 
1201 sputum samples were analyzed, MTB has detected in 268 
(22.31%) samples, and rifampicin resistance was detected in 30 
(2.49%) samples. 2 (33.33%) rifampicin-resistant samples were from 
treatment failures cased [19]. In another study, Rifampicin resistance 
was detected with 100% sensitivity and specificity [8]. A higher rate of 
rifampicin resistance was found in our study compared to the above 
study. The WHO in 2010 permitted the use of the Xpert MTB/RIF 
(CBNAAT) technique for the early and rapid detection of MTB and 
MDR-TB [20]. 
CONCLUSION 
The development of CBNAAT is an important rapid tool to battle 
against TB. CBNAAT testing on EPTB samples showed encouraging 
results. CBNAAT also provides an available part in the early 
diagnosis of smear-negative PTB and EPTB cases. CBNAAT helps in 
the timely diagnosis of TB and detects rifampicin resistance cases 
within 2-3 h. The present study showed that ZN staining along with 
CBNAAT (True NAAT) improves the case detection rate in both 
pulmonary and extrapulmonary TB cases and also showed a 
promising result in the diagnosis of TB in extrapulmonary samples 
compared to pulmonary samples; otherwise, if the ZN results are 
negative, samples should be subjected to the culture, which takes 
months together to detect TB and another couple of months to 
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